Outcome at 3 years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients

被引:87
作者
Khwaja, K [1 ]
Asolati, M [1 ]
Harmon, J [1 ]
Melancon, JK [1 ]
Dunn, T [1 ]
Gillingham, K [1 ]
Kandaswamy, R [1 ]
Humar, A [1 ]
Gruessner, R [1 ]
Payne, W [1 ]
Najarian, J [1 ]
Dunn, D [1 ]
Sutherland, D [1 ]
Matas, AJ [1 ]
机构
[1] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA
关键词
kidney transplant; steroid-free;
D O I
10.1111/j.1600-6143.2004.00443.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Historically, late steroid withdrawal after kidney transplants has been associated with an increased rejection rate. Recently, low rejection rates have been reported for recipients treated with complete avoidance or rapid elimination of steroids. However, follow-up has been short. We herein report on 3- year outcome in recipients whose prednisone was rapidly eliminated and who were maintained on a steroid-free regimen. From 10/1/1999 through 5/1/2003, 349 recipients (254 LD, 95 CAD; 319 in first 30 s) were immunosuppressed with polyclonal antibody (Thymoglobulin), a calcineurin inhibitor, either mycophenolate mofetil or sirolimus, and rapid discontinuation of prednisone. Actuarial 3- year patient survival was 95%; graft survival, 93%. Acute rejection-free graft survival at 1 year was 94%; at 3 years, 92%. There was no difference between LD and CAD. At 2 years, the mean (+/-SE) serum creatinine level for LDs was 1.6+/-0.5 mg/dL; for CAD, 1.6+/-0.4 mg/dL. We have no new cases of PTLD or avascular necrosis; 22 recipients (6%) developed CMV. Currently, 84% of recipients remain prednisone-free. We conclude that excellent 3- year patient and graft survival can be achieved without maintenance prednisone. With such a protocol, steroid-related side-effects are minimal.
引用
收藏
页码:980 / 987
页数:8
相关论文
共 43 条
[11]   BONE LOSS AFTER GLUCOCORTICOID THERAPY [J].
CASCIO, VL ;
BONUCCI, E ;
IMBIMBO, B ;
BALLANTI, P ;
TARTAROTTI, D ;
GALVANINI, G ;
FUCCELLA, L ;
ADAMI, S .
CALCIFIED TISSUE INTERNATIONAL, 1984, 36 (04) :435-438
[12]   Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation [J].
Cattaneo, D ;
Perico, N ;
Gaspari, F ;
Gotti, E ;
Remuzzi, G .
KIDNEY INTERNATIONAL, 2002, 62 (03) :1060-1067
[13]  
CECKA M, 2000, CLIN TRANSPLANTS 199, P1
[14]  
Citterio F, 2001, TRANSPLANTATION, V72, pSS75
[15]   A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. [J].
Cole, E ;
Landsberg, D ;
Russell, D ;
Zaltzman, J ;
Kiberd, B ;
Caravaggio, C ;
Vasquez, AR ;
Halloran, P .
TRANSPLANTATION, 2001, 72 (05) :845-850
[16]   BONE LOSS IN ADULTS RECEIVING ALTERNATE DAY GLUCOCORTICOID THERAPY - A COMPARISON WITH DAILY THERAPY [J].
GLUCK, OS ;
MURPHY, WA ;
HAHN, TJ ;
HAHN, B .
ARTHRITIS AND RHEUMATISM, 1981, 24 (07) :892-898
[17]   Mycophenolate mofetil in renal allograft recipients - A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection [J].
Halloran, P ;
Mathew, T ;
Tomlanovich, S ;
Groth, C ;
Hooftman, L ;
Barker, C .
TRANSPLANTATION, 1997, 63 (01) :39-47
[18]   Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age [J].
Hjelmesaeth, J ;
Hartmann, A ;
Kofstad, J ;
Stenstrom, J ;
Leivestad, T ;
Egeland, T ;
Fauchald, P .
TRANSPLANTATION, 1997, 64 (07) :979-983
[19]  
HRICIK DE, 1993, J AM SOC NEPHROL, V4, P1300
[20]   Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study [J].
Kahan, BD .
LANCET, 2000, 356 (9225) :194-202